Medix Biochemica expands infectious diseases antibody offering with ViroStat acquisition
Operations at ViroStat will remain in Westbrook, Maine, and its employees, including president Douglas McAllister and general manager Duncan McAllister, will join Medix Biochemica following the acquisition.
Steve Ferguson, CEO of Medix, said he was ‘very excited’ to welcome the whole ViroStat team.
"The partnership with ViroStat provides Medix Biochemica with market-leading products for broad range of infectious diseases as well as further strengthens our scientific capabilities and network in this largest diagnostic area of IVD antibodies and antigens,” he said.
“There has been a long-standing business relationship between ViroStat and Medix Biochemica, and we have great respect for what Doug, Duncan and the whole ViroStat team have built over the last 38 years. I am highly excited about the portfolio and cultural fit between our teams and looking forward to jointly growing our business to enable our customers to combat infectious diseases globally".
ViroStat is a manufacturer of antibodies and antigens used for the detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens.
The company is widely known for its high affinity antibodies to Influenza A, Influenza B, RSV and Strep A for use in rapid lateral flow devices.
ViroStat president Douglas McAllister noted that "partnering with Medix Biochemica represents an exciting synergy of complementary product portfolios. ViroStat brings validated antibody pairs especially for rapid test IVDs at a time when worldwide demand for self-testing is poised for rapid growth while our R&D activity endeavors to stay ahead of new and emerging pathogens. We are very pleased and excited to be joining the Medix Biochemica family. This is a great fit."
